CDC25B is involved in cell cycle regulation and DNA damage response and has been targeted by thiostrepton, FDI-6, and siomycin A in preclinical studies for the treatment of platinum-resistant ovarian cancer [142]. This evidence concerns the gene CDC25B and ovarian carcinoma.